* Somatogen Inc., of Boulder, Colo., presented data showing itsrecombinant human hemoglobin delivers oxygen to tissues for use inenergy production as effectively as whole blood.

* Univax Biologics Inc., of Rockville, Md., started a Phase II trial ofHyperGAM+CF, a specific polyclonal designed to prevent and treatrecurring acute lung infections in cystic fibrosis patients.

* VIMRx Pharmaceuticals Inc., of Stamford, Conn., initiated a PhaseI/II dose-response trial of its lead product, VimRxyn, in Thailand inHIV patients.

* Allelix Biopharmaceuticals Inc., of Toronto, received Canadianapproval to begin a Phase II trial of ALX1-11, a recombinant humanparathyroid hormone, for osteoporosis, triggering the start of asecond Phase II study in the U.S. for the same indication. In addition,Allelix, which reported last month Glaxo Canada Inc. ended theirjoint venture development of ALX1-11, has received a payment fromthe London-based pharmaceutical company related to expenses forthe collaboration. (See BioWorld Today, March 16, 1995, p. 2.)

* Biomira Inc., of Edmonton, Canada, began a Phase I safety trial ofBP1-7, a vaccine, for breast cancer. Fourteen patients with metastaticbreast cancer will participate and enrollment is expected to becompleted by the end of this year.

* Gensia Inc., of San Diego, received FDA approval for anabbreviated new drug application for amphotericin B for use as anintravenous anti-fungal therapeutic.

* Houghton Pharmaceuticals Inc., of San Diego, started clinical trialsof HP 228, a cytokine restraining agent, to reduce the negative sideeffects of chemotherapy in advanced cancer patients. The smallmolecule compound is designed to counteract the effects of cytokineswithout interfering with their immune functions.

* ImmuCell Corp., of Portland, Maine, received a $100,000 PhaseSmall Business Innovation Research grant from the National Instituteof Allergy and Infectious Diseases for development of a passiveantibody product to treat diarrhea caused by Escherichia coli.

* Matrix Pharmaceutical Inc., of Menlo Park, Calif., began two PhaseIII trials of AccuSite injectable gel for basal cell cancer. Thecompany also said it completed a Phase III for genital warts andexpects to file a new drug application with the FDA this year.

* Quadra Logic Technologies Inc., of Vancouver, Canada, acquiredan exclusive license to develop and market Switzerland-based Ciba-Geigy Ltd.'s photodynamic therapy drug, zinc phthalocyanine(ZnPc), and other photosensitive compounds. Quadra Logic also saidCiba no longer has an exclusive option for rights to Quadra Logic'sphotodynamic therapy drug, benzoporphyrin derivative, for cancerand psoriasis. To obtain the ZnPc license, Quadra Logic granted Ciba500,000 common share purchase warrants, which can be exercisedduring the next four years.

* Sepracor Inc., of Marlborough, Mass., initiated Phase II trials in theU.S. of R-albuterol for asthma. The b2-agonist is designed to be animproved version of albuterol.

* Sheffield Medical Technologies Inc., of New York, signed anagreement with the Beth Israel Hospital, of Boston, for an expandedclinical study of SCHAL-1, a topical form of an anti-proliferativecompound for treatment of Kaposi's sarcoma. The initial physician-sponsored clinical trial at Beth Israel was completed March 31 andanalysis of the data is expected by the end of the second quarter.

BioWorld

April 6, 1995

Vol. 6, No. 66

APPOINTMENTS AND ADVANCEMENTS

* Alza Corp., of Palo Alto, Calif., named Felix Theeuwes aspresident of Alza Research and Development; James Young asmanaging director of Alza Technology Institute; promoted JamesWissel to vice president of regulatory and quality management;promoted Don Chaisson to vice president of quality management andanalytical sciences; and promoted Mary Prevo to vice president ofenvironmental and product safety.

* Amersham International plc, of Buckinghamshire, England,appointed Jim Brown as managing director for the internationaltrading and technology division.

* Aramed Inc., of San Diego, appointed Bob Peck, part of PerotInvestments, to its board of directors. Paul Laikand was namedpresident and also to the company's board.

* ArQule Inc., of appointed David Coffen to the position of vicepresident of chemistry.

* Canji Inc., of San Diego, named Kenneth Cohen to the newposition of executive vice president and chief operating officer.

* Carrington Laboratories Inc., of Irving, Texas, said Selvi Vescovi,its chairman, will become acting president and CEO.

* CytoProbe Corp., of San Diego, appointed Don Irwine to its board.He is president of a health-care consulting firm.

* Epitope Inc., of Beaverton, Ore., appointed J. Richard George tovice president of scientific affairs for the medical products division.

* GenVec Inc., named Steven Mayer to the new position of vicepresident and chief financial officer, and Paul Fischer to vicepresident for research and development..

* Gilead Sciences Inc., of Foster City, Calif., promoted Howard Jaffeto chief medical officer, Jeffrey Bird to vice president of corporatedevelopment, and William Lee to vice president of pharmaceuticalproduct development.

* Guilford Pharmaceuticals Inc., of Baltimore, named NicholasLandekic vice president of business development and Thomas Seohvice president, general counsel and secretary.

* HemaSure Inc., of Marlborough, Mass., appointed Donald Marecias vice president, North American Sales.

* ICOS Corp., of Seattle, said W. Michael Gallatin will assumeresponsibilities as vice president and scientific director. Thatfollowed the departure of founder Christopher Henney.

* LifeCell Corp., of The Woodlands, Texas, elected James Foster toits board of directors. He is vice president and general manager ofMedtronic Inc.'s heart valve business. It also appointed RandySchwartz as vice president of sales and marketing.

* Megabios Corp., of Burlingame, Calif., appointed BenjaminMcGraw as president and CEO; Rodney Pearlman as vice president,research and development; and Patrick Enright as vice president,finance and business development.

* Metasyn Inc., of Cambridge, Mass., named Susan Flint vicepresident, regulatory affairs.

* Noonan/Russo Communications Inc., of New York, appointedRhonda Chiger as general manager of its new European office inLondon.

* Oncor Inc., of Gaithersburg, Md., named George Scherer, aconsultant, to its board.

* Pharmos Corp., of New York, retained S. Colin Neill as actingchief financial officer.

* Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., namedMurray Goldberg vice president, finance and administration, chieffinancial officer and treasurer.

* RGene Therapeutics Inc., of The Woodlands, Texas, named RobertDe Jager as vice president of clinical affairs.

* Somatix Therapy Corp., of Alameda, Calif., named Jan Drayer tothe new position of executive vice president, pharmaceuticaldevelopment.

* Syntro Corp., of Lenexa, Kan., elected Russell Stern Jr. aschairman of the board of directors.

* Systemix Inc., of Palo Alto, Calif., appointed John Schwartz aspresident and CEO.

* Texas Biotechnology Corp., of Houston, promoted StephenMueller to vice president, administration.

(c) 1997 American Health Consultants. All rights reserved.